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Previous studies showed that polymerized-type I collagen (polymerized collagen) exhibits potent immunoregulatory properties.
This work evaluated the eﬀect of intramuscular administration of polymerized collagen in early and established collagen-
induced arthritis (CIA) in mice and analyzed changes in Th subsets following therapy. Incidence of CIA was of 100% in mice
challenged with type II collagen. Clinimorphometric analysis showed a downregulation of inﬂammation after administration
of all treatments (P<0.05). Histological analysis showed that the CIA-mice group had extensive bone erosion, pannus and
severe focal inﬂammatory inﬁltrates. In contrast, there was a remarkable reduction in the severity of arthritis in mice under
polymerized collagen, methotrexate or methotrexate/polymerized collagen treatment. Polymerized Collagen but not methotrexate
induced tissue joint regeneration. Polymerized Collagen and methotrexate/polymerized collagen but not methotrexate alone
induces downregulation of CD4+/IL17A+ T cells and upregulation of Tregs and CD4+/IFN-γ+ T cells. Thus, Polymerized Collagen
could be an eﬀective therapeutic agent in early and established rheumatoid arthritis by exerting downregulation of autoimmune
inﬂammation.
1.Introduction
Rheumatoid arthritis (RA) is a common systemic disorder
characterized by autoimmunity and chronic inﬂammation
of multiple joints. Collagen-induced arthritis (CIA) is a
well-established animal model of RA [1]. CIA is induced
in genetically susceptible strains of mice by immunization
with type II bovine collagen (CII). Although the eﬀector
mechanisms of inﬂammation ultimately result in pathogenic
lesions of joints (inﬂammatory component of CIA), there is
considerable evidence implicating CII-speciﬁc CD4+ Tc e l l s
as primary mediators of disease induction (T-cell immunity
c o m p o n e n to fC I A )[ 2, 3]. After antigenic stimulation naive
CD4+ T cells develop into diﬀerent types of helper T
cells, each produces its own set of cytokines that mediate
diﬀerent responses in CIA. It has been well documented
that Th1 cells produce interferon (IFN)-γ and interleukin
(IL)-2 and have been considered to be the major mediator
of the disease [4, 5]. However, the notion that CIA is a
Th1-mediated disorder has been challenged by studies using2 Clinical and Developmental Immunology
T h 1 - d e f e c t i v em i c e[ 6]. Mice lacking IFN-γ,I F N - γ receptor,
or IL-12p35 develop accelerated arthritis after induction
of CIA [7, 8]. Furthermore, recent studies have suggested
that highly proinﬂammatory IL-17-producing Th17 cells,
rather than Th1 cells, are central to the pathology of
autoimmune arthritis [9, 10]. IL-17-producing CD4+ T
cells contribute to severe synovitis, pannus formation, joint
destruction in arthritis joints and autoimmune inﬂamma-
tion [6]. On the other hand, there is ample evidence that
CD4+/CD25+/Foxp3+ regulatory T (Treg) cells also play
a critical role on the inhibition of autoimmune reaction.
Thus, a reciprocal relationship between the diﬀerentiation
of Th17 and Treg cells has been reported [11]. Hence,
therapeutic strategies of RA should consider the regulation
of Th17 and Treg diﬀerentiation as well as the inhibition of
proinﬂammatory cells and Th1 cytokines.
In order to shift the cytokine balance to anti-
inﬂammatory cytokines in RA and to delete hyperactive
proinﬂammatory Th17 and Th1 cells that closely associate
with etiology of RA, it is of utmost importance to discover
novel biological substances that can selectively suppress the
function or downregulate activated Th1 and Th17 cells,
whilst at the same time enhance Treg cell function.
This study focuses on the eﬀect of polymerized-type
I collagen on Th subsets and its primary mechanism of
action in early and established CIA in mice. Polymer-
ized Collagen is a γ-irradiated mixture of atelopeptidic
porcine type I collagen and polyvinylpyrrolidone, which
has immunomodulatory properties [12–14]. One percent
Polymerized Collagen addition to synovial tissue cultures
from non-RA and RA cultures does not induce any change
inDNAconcentrationormetabolism.However,theaddition
of the biodrug to RA synovial tissue cultures modiﬁes the
histological and biochemical pattern of ﬁbrosis, without
changing the total collagen content. Polymerized Collagen
induces the recovery of type III collagen at similar levels
to those detected in normal synovial tissue. The biodrug
diminishes the accumulation of dense and tightly packed
type I collagen ﬁbers and contributes to establish similar
tissue architecture to that observed in normal synovium.
Polymerized Collagen induces a decrease of collagenolytic
activity, mainly calcium-independent collagenase activity
(cathepsins) and the increase of TIMP-1, as well as type III
collagen production. The chronic inﬂammatory process is
altered by Polymerized Collagen action, presumably due to
the downregulation of IL-1β and TNF-α, ELAM-1, VCAM-
1, ICAM-1, and Cox-1 [15, 16].
Subcutaneous or intramuscular administration of Poly-
merized Collagen in combination with methotrexate to RA
patients was safe and well tolerated in the treatment of
this pathology [17]. The biodrug induced a statistically
signiﬁcant clinical improvement in basal versus 3- or 6-
month treatment [18]. Besides, intramuscular administra-
tion diminished C-reactive protein (CRP) and rheumatoid
factor (RF) levels, and patients required lower doses of
methotrexate versus placebo. Thirty percent achieved remis-
sion. No diﬀerences in serological or hematological variables
were found. Adverse events were not detected, except pain
lasting <5min at the injection site [18].
In this study, we show that Polymerized Collagen sup-
presses the development of CIA by enhancing a proportion
of Treg cells while simultaneously diminishing Th17 cells
suggesting that Polymerized Collagen ameliorates autoim-
mune arthritis through the regulation of both Treg/Th17
diﬀerentiation and Th1/Th2 balance.
2.MaterialsandMethods
2.1. Mice. Male DBA1/J mice (7-8 weeks old, 20–22g) were
obtained from Harlan S.A. de C.V. (Mexico City, Mexico).
Mice were kept under speciﬁc pathogen-free conditions.
All animals were set aside under standard conditions in
a 12h day/night rhythm with access to food and water
ad libitum. All animal procedures and experiments were
carried according to international guidelines (ICLAS-WHO)
and national law (NOM 062-ZOO-1999). The protocol of
this study was approved by the Animal Care and Research
Committee of the Instituto Nacional de Ciencias M´ edicas y
Nutrici´ on Salvador Zubir´ an.
2.2. Induction of CIA. Arthritis was induced according to
methods as described previously [1]. Chicken CII (SIGMA-
Aldrich Co. St. Louis, MO, USA) was dissolved in 0.05M
acetic acid to a concentration of 2mg/mL at 4◦C, and
emulsiﬁed with an equal volume of complete Freund’s
adjuvant (SIGMA-Aldrich Co.) Male mice were injected
intradermally at the base of the tail with 0.1mL of emulsion
containing 100μg of chicken CII. Twenty-one days after
the primary immunization, mice were boosted with 0.1mL
of the mixture of 2mg/mL chicken CII and incomplete
Freund’s adjuvant (SIGMA-Aldrich Co.) via the same route.
In each experiment, a control group mice were injected with
citric/citrate buﬀer alone.
2.3. Evaluation of Arthritis Severity in Mice with CIA. The
severity of arthritis was measured by scoring each limb from
0 to 4 grades and by summing up the scores of four limbs:
0 = normal; 1 = erythema or swelling of one or several
digits; 2 = erythema and moderate swelling extending
from the ankle to the mid-foot (tarsals); 3 = erythema and
severe swelling extending from the ankle to the metatarsal
joints; 4 = complete erythema and swelling encompassing
the ankle, foot, and digits, resulting in deformity and/or
ankylosis. The maximum score for each animal is thus 16
[3]. Paw edema in each animal was measured with a vernier
(Mitutoyo America Co.). All the evaluations were made by
the same observer.
2.4. Disease Models
2.4.1. Toxicity. Sixteen mice (n = 4 per group) with-
out arthritis were treated by intramuscular administra-
tion once weekly during six weeks with 100μLo f( a )
placebo (citric/citrate buﬀer), (b) polymerized-type I colla-
gen(0.17mgofcollagen),(c)Methotrexate(2.5mg/kg)[19],
or(d)methotrexate(2.5mg/kg)/Polymerized-typeIcollagenClinical and Developmental Immunology 3
(0.17mgofcollagen).Twomiceofeachgroupweresacriﬁced
at the 6th and 13th weeks.
2.4.2. Early Arthritis. Forty-eight male mice (n = 12
per group) were injected with emulsion of chicken CII.
Twenty one days after the primary immunization, mice
were boosted. At the same time, mice were treated with
100μL of (a) placebo (citric/citrate buﬀer), (b) Polymerized-
Type I Collagen, (c) methotrexate (2.5mg/kg) or (d)
methotrexate/Polymerized-Type I Collagen. Six mice of each
group were sacriﬁced at the 6th and 13th weeks.
2.4.3. Established Arthritis. Forty eight male mice (n = 12
per group) were injected with emulsion of chicken CII.
Twenty one days after the primary immunization, mice were
boosted. One week later, mice were treated with 100μLo f( a )
placebo (citric/citrate buﬀer), (b) Polymerized-Type I Col-
lagen, (c) methotrexate, or (d) Methotrexate/Polymerized-
Type I Collagen. Six mice of each group were sacriﬁced at
the 8th and 13th weeks.
2.5. Drug Treatment. One hundred μLo f( a )p l a c e b o
(citric/citrate buﬀer), (b) Polymerized-Type I Collagen, (c)
methotrexate(2.5mg/kg),or(d)methotrexate/polymerized-
type I collagen was intramuscularly administered once
weekly during six weeks.
2.6. Histological Analysis. On day 35 and day 98, the mice
were killed in a carbon dioxide chamber, and the hind
paws were collected, ﬁxed with 10% buﬀered formalin,
and then decalciﬁed in 5% formic acid and embedded
in paraﬃn. Sections (5μm) of whole hind paws were
stained with hematoxylin and eosin and PAS technique.
Histopathological changes were scored by a blinded observer
using the previously reported parameters: 0 = normal joint
structure; 1 = mild changes, synovitis and pannus front with
view discrete cartilage focal erosions; 2 = moderate changes,
accompanying loss of large areas of cartilage, eroding pannus
front and synovial hyperplasia with inﬁltrating mononuclear
cells and polymorphonuclear cells; 3 = severe synovitis,
cartilage, and bone erosion; 4 = total destruction of joint
architecture [20].
2.7. Cell Preparations and Flow Cytometric Analysis. Spleens
were isolated from mice. Splenocytes were stained with
5μL of anti-CD4-FITC-labelled monoclonal antibody (BD
Biosciences, San Jose, Calif, USA) at room temperature
in the dark for 20min. After two washes, cells were per-
meabilized with 200μL of cytoﬁx/cytoperm solution (BD
Biosciences) at 4◦C for 20min. After two washes with
permwash solution (BD Biosciences), cells were stained for
intracellular cytokines and transcription factors with 5μL
of anti-IL-17A-PE-labelled, anti-IFN-γ-PE-labeled anti-IL-
4-PE-labelled,andPE-labelledanti-Foxp3forTregs(BDBio-
sciences),for30minat4◦Cinthedark.Finally,afterwashing
with permwash solution, splenocytes were analyzed by ﬂow
cytometrywithaFACScan(BDBiosciences).Atotalof10000
events were recorded for each sample and analyzed with the
CellQuest software (BD Biosciences). Results are expressed
as the relative percentage of IL-17A, IFN-γ, IL-4, or Foxp3-
expressing cells in each gate. In order to avoid false positive
PE results and also for setting compensation for multi-
color ﬂow cytometric analysis, we performed instrument
calibration/standardization procedures each day according
to established protocols of our laboratory. Brieﬂy, we run
an unstained (autoﬂuorescence control) and permeabilized
PBMCs sample. Autoﬂuorescence control (unstained cells)
was compared with single-stained cell-positive controls to
conﬁrm that the stained cells were on scale for each
parameter. Besides, BD Calibrite 3 beads were used to
adjust instrument settings, set ﬂuorescence compensation,
and check instrument sensitivity (BD CaliBRITE, BD Bio-
sciences).
2.8. NFκB/IκBα Flow Cytometric Analysis. Splenocytes were
permeabilized with 200μL of cytoﬁx/cytoperm solution (BD
Biosciences) at 4◦C for 20min. After two washes with
permwash solution (BD Biosciences), cells were stained
for intracellular transcription factors with 5μL of anti-
NFκBp65-FITC-labelled monoclonal antibody (Santa Cruz,
Calif, USA) and 5μL of anti-IκBα PE-labeled monoclonal
antibody (IκBα binds to the p65 subunit of p50–p65
heterocomplex through ankyrin repeats) (Santa Cruz), for
30min at 4◦C in the dark. After washing with permwash
solution, splenocytes were analyzed by ﬂow cytometry with
a FACScan (BD Biosciences). A total of 10000 events were
recorded for each sample and analyzed with the CellQuest
software (BD Biosciences). Results are expressed as the
relative percentage of NFκBp65+/IκBα+ c e l l si ne a c hg a t e .
2.9. Statistical Analysis. Statistical analysis was performed
using the SigmaStat11 program by one way analysis of vari-
ance on Ranks and by Holm-Sidak method for all pairwise
multiple comparison procedures. Data were expressed as the
mean ± SEM. The P-values smaller than or equal to 0.05
were considered as signiﬁcant.
3. Results
3.1. Eﬀect of Polymerized-Type I Collagen on Toxicity Model.
Treatments evaluated in this study have no in vivo toxicity
for mice. It was evaluated by macroscopical and histopatho-
logical analysis of kidneys, heart, lungs, spleen, lymph nodes,
and hind paws. All tissues resembled normal architecture.
No inﬂammatory inﬁltrates or other abnormalities were
observed (data not shown).
3.2. Eﬀect of Polymerized-Type I Collagen on Attenuation
of Early and Established Arthritis Model. To investigate the
eﬀect of polymerized-type I collagen in the progression of
CIA, intramuscular administration of biodrug was initiated
one week before booster of CII. The dose selected was
based on our previous in vitro and in vivo results [16,
17]. Typically, DBA1/J mice developed signs of arthritis
after the second immunization given at 21 day after the
ﬁrst CII immunization and showed maximum arthritis4 Clinical and Developmental Immunology
around day 35–42 (Figure 1). Mice of early arthritis model
treated with polymerized-type I collagen showed signiﬁcant
reductions in the severity of CIA compared with placebo
(Figures 1(a) and 1(b)). On day 8–16, arthritis score and
paw thickness reached their peaks. Polymerized Collagen
and methotrexate/Polymerized Collagen treatments more
than methotrexate alone signiﬁcantly suppressed arthritis
severity scores. A similar pattern of response was observed
on established arthritis model (Figures 1(c) and 1(d)).
Paw thickness was normal in early and established CIA
models in groups treated with Polymerized Collagen and
methotrexate/Polymerized Collagen (Figures 1(a) and 1(c)).
However, methotrexate treatment does not diminish edema
and induces fever (≈ 1.5
◦C).
3.3. Histopathological Analysis of the Polymerized-Type I
Collagen Eﬀect on Early and Established Arthritis Model.
Histopathological analysis was performed on hind paws
of CIA mice harvested on day 35 and 98 after booster
immunization by two blinded investigators. Representa-
tive images of hematoxylin and eosin-stained and PAS-
stained joint tissue sections from the groups treated with
placebo, Polymerized-Type I Collagen, methotrexate, and
methotrexate/polymerized-type I collagen are presented in
Figure 2. Mice showed typical arthritis, which is character-
ized by extensive inﬁltration of inﬂammatory cells, synovial
hyperplasia, and bone erosion. Treatment with polymerized-
type I collagen showed no signs of inﬂammation. Whereas
methotrexate/polymerized-type I collagen resulted in signif-
icant reduction in cellular inﬁltration, pannus formation,
and destruction of cartilage and bone in arthritic joints
with a low pathogenic score of CIA mice in both models.
Methotrexate induced other tissue abnormalities such as the
presence of nodules (amorphous ﬁbrin tissue like) and a
l o wq u a l i t yw o u n dr e p a i rt i s s u ea sw e l la si n ﬂ a m m a t o r y
inﬁltrates. The eﬀect of polymerized-type I collagen and
methotrexate/polymerized-type I collagen was sustained
until the second sacriﬁce. Thus, histological evaluations
conﬁrmed the characteristic arthritic lesions and showed an
excellent correlation with clinical grading (Figure 2).
3.4. Polymerized-Type I Collagen Modulates Th Spleen Cell
Population on Early and Established CIA Model. To inves-
tigate Th cytokine patterns, mice were sacriﬁced by a
blinded researcher at two diﬀerent periods after booster
immunization, on day 35 and 98. One control mice group
without CIA was included. Cell suspensions from spleens
were obtained and analyzed for ex vivo cytokine production
by intracellular staining using ﬂow cytometry (Figure 3).
Proportions of Th17 were consistently ∼0.7% in spleno-
cytes from mice without CIA. Higher percentage of IL-17-
producing CD4+ T cells were determined in CIA mice in
early arthritis (2.5% and 4.3%, for the ﬁrst and second
sacriﬁce,resp.Figures4(a)and4(b))andestablishedarthritis
(2.4% and 3.6%, for the ﬁrst and second sacriﬁce, resp.
Figures 4(c) and 4(d)). A reduction on percentage of IL-
17A-producing CD4+ T cells similar to normal levels was
determined in mice with early and established arthritis
treated with polymerized-type I collagen (1.2% and 1.3%
for the ﬁrst and second sacriﬁce in early arthritis, Figures
4(a) and 4(b) and 0.5% and 1.3% for the ﬁrst and second
sacriﬁce in established arthritis Figures 4(c) and 4(d))a n d
methotrexate/Polymerized Type I Collagen (0.8% and 1.4%
fortheﬁrstandsecondsacriﬁceinearlyarthritis,Figures4(a)
and 4(b) and 0.7% and 1.3% for the ﬁrst and second sacriﬁce
in established arthritis Figures 4(c) and 4(d)). Methotrexate
treatment was not so eﬀective compared to the biodrug and
the mixture of it with methotrexate (1.4% and 2.2% for the
ﬁrst and second sacriﬁce in early arthritis, Figures 4(a) and
4(b) and 1.2% and 1.1% for the ﬁrst and second sacriﬁce
in established arthritis Figures 4(c) and 4(d)). Polymerized-
Type I Collagen and methotrexate/Polymerized Collagen
treatments had a sustained eﬀect in early and established
arthritis model until the second sacriﬁce (follow up) on the
percentage of IL-17A-producing CD4+ T (Figures 4(b) and
4(d)).IFN-γ-producingTh1cellswerealsoinducedbyCIIin
vivoimmunization,andtheirfrequencywassimilarthanthat
of Th17 in early and established arthritis. However, IFN-γ
producing Th1 cells were lower after treatment in established
arthritis model (Figures 4(c) and 4(d)).
Proportions of Treg cells were consistently ∼3.0% in
splenocytes from mice without CIA. Lower percentage of
Treg cells were determined in CIA mice in early arthritis
(2.2% and 1.6%, for the ﬁrst and second sacriﬁce, resp. Fig-
ures 4(a) and 4(b)) and established arthritis (1.5% and 1.2%,
for the ﬁrst and second sacriﬁce, respectively, Figures 4(c)
and 4(d)). A statistically signiﬁcant increase on percentage of
Treg cells was determined in mice with early and established
arthritis treated with polymerized-type I collagen (4.5% and
3.5% for the ﬁrst and second sacriﬁce in early arthritis,
Figures 4(a) and 4(b) and 2.4% and 2.5% for the ﬁrst and
secondsacriﬁceinestablishedarthritisFigures4(c)and4(d))
and methotrexate/Polymerized Collagen (4.4% and 3.0% for
the ﬁrst and second sacriﬁce in early arthritis, Figures 4(a)
and 4(b) and 2.4% and 1.7% for the ﬁrst and second sacriﬁce
in established arthritis Figures 4(c) and 4(d)). Methotrexate-
treated mice had a slightly increased response on percentage
of Treg cells (2.0% and 1.6% for the ﬁrst and second sacriﬁce
in early arthritis, Figures 4(a) and 4(b) and 1.2% and 1.8%
for the ﬁrst and second sacriﬁce in established arthritis
Figures 4(c) and 4(d)). However, this subpopulation was
reduced in 50% compared to mice without CIA.
Taken together, these results indicate that polymerized-
type I collagen is a biological compound that downregulated
Th17 and upregulated Treg cell diﬀerentiation in vivo on
early and established arthritis.
3.5. Eﬀect of Polymerized-Type I Collagen on NF-κBo nE a r l y
and Established CIA Model. We infer that polymerized-type
I collagen mechanism of action might be mediated through
the regulation of certain transcription factors such as NF-
κB and AP-1. In particular, NF-κB regulates the expres-
sion of proinﬂammatory enzymes, cytokines, chemokines,
immunoreceptors, and cell adhesion molecules as well as
apoptosis.Inthelightofthisknowledge,NF-κBp65andIκBα
were analyzed in splenocytes ex vivo (Figure 5). PercentageClinical and Developmental Immunology 5
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Figure 1: Preventive and therapeutic eﬀects of polymerized-type I collagen on mouse CIA. (a) Paw thickness in early arthritis model.
One hundred microliters of Polymerized Collagen, 100μL of Polymerized Collagen, and 100μL of methotrexate (2.5mg/kg) or 100μLo f
methotrexate (2.5mg/kg)/Polymerized Collagen were administered intramuscular once a week during 6weeks at the same time of that of
the booster. Citric/citrate buﬀer was injected as a vehicle control. Data represent mean ± SEM (each group, n = 6). (b) Clinical arthritis
score in early arthritis model (n = 6). (c) Paw thickness in established arthritis model. One hundred microliters of Polymerized Collagen,
100μL of Polymerized Collagen, and 100μL of methotrexate (2.5mg/kg) or 100μL of methotrexate (2.5mg/kg)/Polymerized Collagen were
administered intramuscularly once a week during 6 weeks. Treatments were started on 14 days after the booster. Citric/citrate buﬀer was
injected as a vehicle control. Data represent mean ± SEM (each group, n = 6). (d) Clinical arthritis score in established arthritis model
(n = 6). ∗P<0.05.
of NF-κBp65 (∼1.5%), IκBα (∼1.1%), and NF-κB/IκBα cells
(∼2.2%) were consistently found in splenocytes from mice
without CIA.
HigherpercentageofIκBα+ andNF-κB+/IκBα+ cellswere
found in CIA mice under polymerized-type I collagen and
methotrexate/polymerized-type I collagen treatment in early
arthritis in the ﬁrst and second sacriﬁce compared with CIA
mice without treatment (Figures 5(a) and 5(b)). Interest-
ingly, normal levels of NF-κBp65 were observed in CIA mice
under Polymerized Collagen and methotrexate/Polymerized6 Clinical and Developmental Immunology
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Figure 2: Preventive eﬀect of polymerized-type I collagen on the histological damage in CIA mice. (a) Representative section of joint
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Figure 4: Eﬀect of polymerized-type I collagen on the ex vivo intracellular cytokine production and on CD4+ T cell subsets regulation in
splenocytes. (a) Spleen cells obtained immediately ex vivo in early arthritis model on day 35 after booster immunization. (b) Splenocytes
obtained immediately ex vivo in early arthritis model on day 98 after booster immunization. (c) Spleen cells obtained immediately ex
vivo in established arthritis model during ﬁrst sacriﬁce. (d) Splenocytes obtained from established arthritis model during second sacriﬁce.
Intracellular production of IL-17A, IL-4, IFN-γ, and Foxp3 by CD4+ T cells was detected by ﬂow cytometry. Results are representative of
6 mice analyzed in each group. Horizontal dotted line represents mean normal values, obtained from mice (n = 3) without CIA. Data
represent mean ± SEM. ∗P<0.05.
Collagen treatment in early arthritis during second sacriﬁce
(Figure 5(b)). In established arthritis model, normal per-
centages of NF-κBp65 were found in mice under Polymer-
ized Collagen, methotrexate, or methotrexate/Polymerized
Collagen treatment in the ﬁrst and second sacriﬁce (Figures
5(c) and 5(d)), as well as, IκBα levels during second sacriﬁce
(Figure 5(d)). Finally, NF-κB+/IκBα+ cells were increased in
treated mice compared with CIA mice in the ﬁrst and second
sacriﬁce (Figures 5(c) and 5(d)).
4. Discussion
In the present work, we demonstrated that polymerized-type
I collagen as monotherapy as well as in combination with
methotrexateexhibitsbothpreventiveandtherapeuticeﬀects
on mouse CIA, through downregulation of Th17 subset and
upregulation of Treg cells.
Th17 cells represent a new subset of T helper cells, which
mainly produce IL-17A and IL-17F, and, to a lesser extent,8 Clinical and Developmental Immunology
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Figure 5: Eﬀect of polymerized-type I collagen on the ex vivo NF-κB and IκB-α in splenocytes. (a) Spleen cells obtained immediately ex
vivo in early arthritis model on day 35 after booster immunization. (b) Splenocytes obtained immediately ex vivo in early arthritis model
on day 98 after booster immunization. (c) Spleen cells obtained immediately ex vivo in established arthritis model during ﬁrst sacriﬁce.
(d) Splenocytes obtained from established arthritis model during second sacriﬁce. Intracellular levels of NF-κBp65 and IκBα cells were
detected by ﬂow cytometry. Results are representative of 6 mice analyzed in each group. Horizontal dotted line represent mean normal
values, obtained from mice (n = 3) without CIA. Data represent mean ± SEM. ∗P<0.05.
TNF-α and chemokines. The ﬁrst report on IL-17-producing
CD4+ T cells came from a study of in vitro-primed TCR
transgenic T cells where the addition of Borrelia burgdorferi
lysate induced IL-17 production [21].
However, in the last years, the outstanding importance
of Th17 cells has most convincingly been demonstrated
in the pathogenesis of organ-speciﬁc autoimmune diseases.
This was in fact, a broken paradigm, as previously Th1
cells had been regarded as the preponderant cell subpop-
ulation driving autoimmune tissue damage. This concept
was challenged when it became clear that IFN-γ and IFN-
γ-receptor deﬁcient mice were not protected from CIA but
developed more severe disease [22–26]. Moreover, IL-17-
deﬁcient mice or mice treated with anti-IL-17 antibody
reduce joint inﬂammation, cartilage destruction, and bone
erosion [27–29]. Collectively, these data corroborate the
importance of Th17 cells for the induction of autoimmune
tissue inﬂammation.
Our results are in agreement with the subcutaneous,
intramuscular or mucosal administration of type II collagen
or altered CII263–272 peptide that suppress Th17 cells
and expand regulatory T cells in the early stage of the
disease [30–33]. However, the mechanism of action could
be quite diﬀerent meanwhile altered CII263–272 peptidesClinical and Developmental Immunology 9
could bind to RA-associated HLA-DR4/1 with no T cell
stimulating eﬀects and might inhibit T cell activation in
RA, polymerized-type I collagen could be acting likely as a
tolerogenic molecule.
Methotrexate therapy is associated with depletion of all
CD4+ T cell subsets, including Tregs, and also with the
development of rheumatoid nodules following improvement
of arthritis, as has been reported in previous studies [34–36].
Methotrexate/polymerized-typeIcollageninducedeﬀec-
tivedownregulationofinﬂammatoryTcellsubsetsalthough,
unexpectedly, there was no synergistic eﬀect between both
treatments.
On the other hand, it is well known that impaired Treg
function is also associated with pathogenesis of autoimmune
disease, and that CD4+/CD25+/Foxp3+ cells represent one of
the major Treg cells involved in susceptibility/resistance to
autoimmunity [37]. In the present experiments, we found
that the percentage of Treg cells in the spleen of CIA mouse
was signiﬁcantly upregulated by Polymerized Collagen and
methotrexate/polymerized-type I collagen treatments but
notbymethotrexatealone.Theseresultssupportthehypoth-
esis that the reciprocal downregulation of IL-17 expression
at the time of upregulation of Foxp3 induced by Polymerized
CollagenisinvolvedinthebalanceofTreg/Th17,andthiscan
lead to prevention or full blown autoimmune arthritis.
It is important to note that, 28 days after the last
polymerized-type I collagen or methotrexate/polymerized-
type I collagen administration, mice were without any sign
of disease. Besides, side eﬀects were not determined in mice
under Polymerized-Type I Collagen, albeit methotrexate
induced other tissue abnormalities such as the presence of
nodules (amorphous ﬁbrin tissue like) and hyperthermia
(≈ 1.5
◦C) determined during all the study, which was also
previously described by Lange et al. [19].
Furthermore,animals treatedwith PolymerizedCollagen
in the early and established CIA model not only remained
without clinical manifestations of the disease and without
hyperthermia, but their joints were free from inﬂammatory
cell inﬁltrates. Indeed, histological sections of ankle from
polymerized-type I collagen but not methotrexate treatment
showed normal joint tissues, without inﬂammatory inﬁl-
tration of bone erosions and preservation of proteoglycans
content (PAS staining), compared to CIA. Thus, histological
evaluations conﬁrmed the characteristic arthritic lesions and
showed an excellent correlation with clinical grading.
NF-κB has been often termed a “central mediator of the
immune response,” because of its critical role in the control
of key physiological and pathological states, from immune to
autoimmune response. Regulation of the so-called “canoni-
cal” NF-κB transcription factor by the IKK complex involves
its cytosolic-to-nuclear translocation mediated by the phos-
phorylation of the inhibitory molecule IκB-α [38]. Imbal-
ance of NF-κBa n dI κBα has been associated with develop-
ment of common inﬂammatory diseases including ulcerative
colitis, Crohn’s disease, rheumatoid arthritis, systemic lupus
erythematosus, psoriatic arthritis, giant cell arthritis, type 1
diabetes, multiple sclerosis, celiac disease, and Parkinson’s
disease,aswellassusceptibilityofseveralcancers,suchasoral
squamous cell carcinoma, colorectal cancer, hepatocellular
carcinoma, breast cancer, and myeloma. In the present work,
wefoundthatPolymerizedCollagenaloneorincombination
with methotrexate is capable to increase IκB-α inhibitor
in early and established arthritis models. Thus, it is not
preposterous to speculate that, this biodrug could contribute
considerably to the downmodulation of inﬂammation and
tissue regeneration eﬀects observed.
Summing up, polymerized-type I collagen may be one of
the novel therapeutic candidates that can suppress autoim-
mune inﬂammation by regulating the T cell diﬀerentiation
and the balance of pathogenic and regulatory T cells, in such
a way that proinﬂammatory Th17 cells are downregulated
and Treg cells are expanded. Besides, Polymerized Colla-
gen induces downregulation of proinﬂammatory cytokine
expression and tissue regeneration that could be regulated
probably through NF-κB modulation. Our results shed
further light into the preponderant role of polymerized-type
I collagen in downregulation of inﬂammation and tissue
regeneration and certainly deserve to be studied in depth in
order to determine the precise mechanism(s) of action.
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